A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

被引：0
|
作者：
Grant, Cliona [1 ]
Dunleavy, Kieron [1 ]
Hessler, Julieanne [1 ]
Steinberg, Seth M. [2 ]
Pittaluga, Stefania [3 ]
Jaffe, Elaine S. [3 ]
Wilson, Wyndham H. [4 ]
机构：
[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Biostat & Data Management Sect, Rockville, MD USA
[3] NCI, Pathol Lab, Bethesda, MD 20892 USA
[4] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3709.3709
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3709
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase I/II Study of a Hybrid Schedule of Flavopiridol in Relapsed/Refractory Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
    Dunleavy, Kieron
    Shapiro, Geoff
    Disinski, Megan
    Chirieac, Lucian
    Pittaluga, Stefania
    Jaffe, Elaine S.
    Janik, John E.
    Wiestner, Adrian
    Wilson, Wyndham H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E27 - E27
  • [22] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [23] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 45 - 56
  • [24] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [25] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [26] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [27] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [28] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Harris, Leonard Jeff
    Patel, Kruti
    Martin, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
  • [29] Phylogenetic Evolution in Refractory/Relapsed Diffuse Large B-Cell Lymphoma
    Ruminy, Philippe
    Rainville, Vinciane
    Mareschal, Sylvain
    Etancelin, Pascaline
    Joly, Berangere
    Picquenot, Jean-Michel
    Bastard, Christian
    Tilly, Herve
    Jardin, Fabrice
    BLOOD, 2012, 120 (21)
  • [30] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
    Kesireddy, Meghana
    Lunning, Matthew A.
    ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
12345